Our Services

Other Trials

Mutation Driven Trials

The trials listed below are for patients with a specific genomic alteration or rearrarangement. A genomic alteration or rearrangement is a change in the DNA within a gene, which can affect the way a cell works. Some genomic alterations are normal, but for patients with cancer, these alterations may be driving the cancer to grow. Sometimes, multiple alterations are causing a patient's cancer to grow. New treatments, called targeted therapies, target the genomic alterations that are causing the cancer to grow.

Novel TKI for Solid Tumors with NTRK1/2/3, ROS1, or ALK Gene Rearrangements Clinical Trial

  • Study name: STARTRK-2
  • Trial for patients with locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement
  • Patients may have received prior treatment, but may also be treatment naïve
  • All patients will receive targeted therapy with Entrectinib, an oral TKI
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Kimberly Young, at 707-521-3836 or at Tracy.Foster@stjoe.org.